NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-HS-20-002 from the NIH Guide for Grants and Contracts. This initiative will fund the dissemination and implementation of PCOR clinical and organizational findings into primary care practices to improve healthcare quality with a focus on cardiovascular care. AHRQ is particularly interested in applications from States with the highest cardiovascular disease (CVD) burden. The initiative will accomplish this goal by catalyzing the development of a sustainable, State-based external primary care quality improvement (QI) support infrastructure to expand the States current and future capacity to disseminate and implement PCOR evidence into primary care practice.
Notice NOT-GM-20-019 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-012 from the NIH Guide for Grants and Contracts
Notice NOT-DA-20-032 from the NIH Guide for Grants and Contracts
Notice NOT-AT-20-004 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-026 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-030 from the NIH Guide for Grants and Contracts
Notice NOT-MD-20-014 from the NIH Guide for Grants and Contracts
Notice NOT-GM-20-023 from the NIH Guide for Grants and Contracts
Notice NOT-MH-20-037 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-115 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to transition the core resources and biomedical research activities of Centers of Biomedical Research Excellence (COBRE) into independence and sustainability.
Funding Opportunity RFA-DA-20-028 from the NIH Guide for Grants and Contracts. NIDA is interested in research that addresses research gaps related to the delivery of integrated treatment services for HIV and opioid use disorder (OUD) among the justice-involved population in the US, with a goal of improving treatment management and implementation. A quarter of people with HIV pass through the justice system each year, making it an important system for HIV prevention and treatment. Community re-entry from incarceration is a time of heightened risk for opioid relapse, mortality, HIV risk behaviors, and discontinuation of HIV treatment. Given these elevated levels of risk, justice-involved PWID should be prioritized for screening and linkage to the full continuum of HIV prevention and treatment services, including Pre-exposure prophylaxis (PrEP) and highly active antiretroviral therapy (HAART). There is a need to better understand the effectiveness of the clinical interventions as received in this population, as well as the methods by which those interventions are delivered (navigation/mobile services).
Notice NOT-TR-20-010 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-20-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit applications for the Vaccine and Treatment Evaluation Units (VTEUs) to implement clinical site protocols (clinical research, clinical trials) for evaluating vaccines, other preventive biologics, therapeutics, diagnostics, including prognostic and predictive markers, and devices for the treatment and prevention of infectious diseases as part of NIAID Infectious Diseases Clinical Research Consortium (IDCRC). A companion FOA solicits applications for the Leadership Group for the Infectious Diseases Clinical Research Consortium, hereafter referred to as the Leadership Group (LG), which provides for overall administrative and scientific leadership for the clinical research and clinical trials conducted. While the primary scientific focus will be on product evaluation for NIAID priority areas, including malaria/neglected tropical diseases, sexually transmitted infections, respiratory infections, and enteric diseases, the VTEUs must also provide surge capacity to address emerging infectious diseases
Notice NOT-LM-20-006 from the NIH Guide for Grants and Contracts
Notice NOT-DE-20-012 from the NIH Guide for Grants and Contracts
Notice NOT-DE-20-011 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-114 from the NIH Guide for Grants and Contracts. The High-End Instrumentation (HEI) Grant program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, high throughput robotic screening systems, and biomedical imagers.
Funding Opportunity PAR-20-112 from the NIH Guide for Grants and Contracts. The Shared Instrumentation for Animal Research (SIFAR) Grant Program encourages applications from groups of NIH-funded investigators to purchase or upgrade scientific instruments necessary to carry out animal experiments in all areas of biomedical research supported by the NIH. Applicants may request clusters of commercially available instruments configured as specialized integrated systems or as series of instruments to support a thematic well-defined area of research using animals or related materials. Priority will be given to uniquely configured systems to support innovative and potentially transformative investigations. This FOA supports requests for state-of-the art commercially available technologies needed for NIH-funded research using any vertebrate and invertebrate animal species. This funding opportunity announcement (FOA) does not support requests for single instruments. At least one item of the requested instrumentation must cost at least $50,000, after all applicable discounts. No instrument in a cluster can cost less than $20,000, after all applicable discounts. There is no maximum price requirement; however, the maximum award is $750,000.
Funding Opportunity PAR-20-113 from the NIH Guide for Grants and Contracts. The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems. The minimum award is $50,000 of direct costs. There is no maximum price limit for the instrument; however, the maximum award is $600,000 of direct costs. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance, spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.